Stockscreener 앱 받기
8.29
2.93%
-0.25
시간 외 거래:
8.06
-0.23
-2.77%
Armata Pharmaceuticals Inc 주식(ARMP)의 최신 뉴스
Armata Pharmaceuticals (ARMP) Delays Financial Results Release - GuruFocus
Armata Pharmaceuticals delays announcement of fourth quarter and full-year 2025 results and provides corporate update - marketscreener.com
Armata Pharmaceuticals delays Q4 2025 results, gets FDA approval - Investing.com
Armata Highlights AP-SA02 Progress Amid Earnings Release Delay - TipRanks
Armata Pharmaceuticals delays 2025 results, wins QIDP and readies Phase 3 for AP-SA02 - TradingView
Armata Pharmaceuticals (ARMP) delays 2025 results, advances AP-SA02 toward Phase 3 - Stock Titan
Armata pushes back earnings as FDA backs Phase 3 staph blood infection study - Stock Titan
HC Wainwright reaffirms buy on Armata Pharmaceuticals, Inc. (ARMP) after FDA nod - MSN
Armata Pharmaceuticals (ARMP) CBO reports tax-withheld share disposition - Stock Titan
Pseudomonal Infections Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Therapeutics Landscape - The Manila Times
Pseudomonal Infections Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags - Seeking Alpha
Armata Pharmaceuticals (ARMP) Projected to Post Earnings on Thursday - MarketBeat
Director at Armata (NASDAQ: ARMP) receives 25,640 stock options grant - Stock Titan
Armata (NASDAQ: ARMP) director receives 25,640 stock options at $11.61 strike - Stock Titan
Armata Pharmaceuticals (ARMP) director receives grant of 25,640 stock options - Stock Titan
Armata Pharmaceuticals (ARMP) grants director 25,640 stock options - Stock Titan
Published on: 2026-03-08 06:18:18 - baoquankhu1.vn
Will Armata Pharmaceuticals Inc. stock return to pre crisis levelsNew Guidance & Risk Controlled Swing Alerts - Naître et grandir
New Strong Sell Stocks for April 24th - MSN
Will Armata Pharmaceuticals Inc. stock outperform growth indexesQuarterly Portfolio Summary & Verified Technical Trade Signals - Naître et grandir
ARMPAmpliPhi Biosciences Announces Planned One-for-Ten Reverse Stock Split - mx.advfn.com
H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod - Yahoo Finance
Weekly Buzz: MGNX's LINNET Trial On Hold; ETON, ALUR Get FDA Nod; GILD Snaps Up ACLX - RTTNews
ARMP Should I Buy - Intellectia AI
Armata Pharmaceuticals (ARMP) Price Target Increased by 25.00% to 15.30 - Nasdaq
H.C. Wainwright lowers Armata Pharmaceuticals stock price target to $15 By Investing.com - Investing.com Canada
ARMP: HC Wainwright & Co. Raises Price Target to $15 | ARMP Stoc - GuruFocus
Armata Pharmaceuticals (ARMP) Receives FDA Designation for AP-SA - GuruFocus
Armata Pharmaceuticals stock gains on FDA designation By Investing.com - Investing.com Canada
Armata Pharmaceuticals stock gains on FDA designation - Investing.com India
Armata Says FDA Grants Qualified Infectious Disease Product Designation to Complicated Bacteremia Treatment - marketscreener.com
Armata Gains QIDP Status for AP-SA02 Bacteremia Therapy - TipRanks
Armata Pharmaceuticals receives FDA qualified infectious disease product designation - marketscreener.com
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product Designation - TradingView
Armata Pharmaceuticals wins FDA QIDP for AP-SA02, enabling 5 years exclusivity and Fast Track eligibility - TradingView
FDA grants QIDP designation to Armata (ARMP) phage therapy AP-SA02 - Stock Titan
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 - PR Newswire
Growth Value: What analysts say about Armata Pharmaceuticals Inc stock2025 Breakouts & Breakdowns & Fast Gain Stock Tips - baoquankhu1.vn
Options Flow: Is HFBL a turnaround storyMarket Volume Report & AI Driven Stock Movement Reports - baoquankhu1.vn
ARMP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Sees Significant Increase in Short Interest - MarketBeat
Is Armata Pharmaceuticals Inc. a cyclical or defensive stockJuly 2025 Drop Watch & Safe Investment Capital Preservation Plans - mfd.ru
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update - MarketBeat
MACD Signal: What analysts say about Armata Pharmaceuticals Inc stockJuly 2025 Analyst Calls & Safe Capital Growth Stock Tips - baoquankhu1.vn
Armata Pharmaceuticals FY2025 EPS Boosted by HC Wainwright - MarketBeat
Aug Closing: What is RADCOM Ltds debt to equity ratioMarket Movers & High Accuracy Swing Trade Signals - baoquankhu1.vn
AI Stocks: Can Armata Pharmaceuticals Inc grow without external fundingMarket Volume Summary & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Armata Pharmaceuticals (ARMP) price target increased by 33.33% to 12.24 - MSN
Phage Therapy Market Set to Witness Significant Growth - openPR.com
Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX), Armata Pharmaceuticals (ARMP) and Halozyme (HALO) - The Globe and Mail
Armata Extends Innoviva Credit, Warrants and Voting Pact - The Globe and Mail
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Stock Price Up 2%Time to Buy? - MarketBeat
Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains? - MSN
Will Armata Pharmaceuticals Inc. stock gain from lower inflationQuarterly Market Summary & Comprehensive Market Scan Reports - bollywoodhelpline.com
Published on: 2026-01-19 10:14:54 - baoquankhu1.vn
Armata Pharmaceuticals (ARMP) Price Target Increased by 33.33% to 12.24 - Nasdaq
Block Trades: Is Armata Pharmaceuticals Inc stock a smart retirement pickTrade Risk Assessment & Growth Focused Stock Pick Reports - baoquankhu1.vn
Armata Wins FDA Support to Advance Bacteriophage to Phase 3 - TipRanks
Armata Pharmaceuticals Advances AP-SA02 to Phase 3 Study - TradingView — Track All Markets
C O R R E C T I O N -- Armata Pharmaceuticals, Inc./ – Company Announcement - Financial Times
1.20%
0.06%
자본화:
|
볼륨(24시간):